UCB refocuses and cuts workforce 17%
UCB is moving forward with efforts to focus on CNS disorders and immunology and plans to cut around 2,000 jobs as part of its SHAPE restructuring program.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs